propranolol and semaglutide A network meta-analysis backed weight-loss benefits with several GLP-1 receptor agonists, with less certainty for newer-generation agents. Read more at the link in bio Dr. Blitshteyn and her research

Importantly, genetic variations within GIP receptors across different species, make the GIP system complex compared to the more conserved GLP-1 system

Saxenda (Liraglutide) FDA approval: 2014 for chronic weight management Indicated population: Adults with BMI 30, OR Adults with BMI 27 with at least one weight-related condition Also available as: Victoza (lower dose, approved for Type 2 diabetes) Ozempic (Semaglutide) FDA approval: 2017 for Type 2 diabetes Indicated population: Adults with Type 2 diabetes as adjunct to diet and exercise Not approved for: Weight loss (though commonly prescribed off-label) Wegovy (Semaglutide) FDA approval: 2021 for chronic weight management Indicated population: Adults with BMI 30, OR Adults with BMI 27 with at least one weight-related condition Adolescents aged 12+ with obesity Same medication as Ozempic: Different dosing and FDA indication Practical Implications The regulatory distinctions matter for: Insurance coverage: Medications are often covered only for their approved indications

"Based on accumulated evidence, it does not seem like GLP-1 drugs when used during the months after conception increase the risk of common (adverse) outcomes substantially

Your diagnosis affects coverage

Lai HH, Newcomb C, Harte S et al: Comparison of deep phenotyping features of ucpps with and without hunner lesion: A mapp-ii research network study

For best before and batch, see base.